Phillips-Medisize expands product portfolio with pen injector platform that reduces pharmaceutical costs, risks and market barriers

Phillips-Medisize expands product portfolio with launches aimed at lowering pharmaceutical costs,

Risks and Market Barriers to Pen Injector Platforms

•The world's leading and customer-preferred drug delivery device company offers market-ready prefilled pen syringes for accelerated delivery of a wide range of therapeutics

•With global integration of drug delivery solutions, pharmaceutical customers are able to conduct large-scale production in multiple regions around the world

•With a comprehensive set of end-to-end capabilities, the company offers combination medical devices off-the-shelf to accelerate product time-to-market

HUDSON, Wis. – February 2, 2023 – Phillips-Medisize, a Molex company, a leader in the design and manufacturing of devices for drug delivery and diagnostic and therapeutic technologies, is expanding its product portfolio with the launch of a once-in-a-lifetime product for pharmaceutical companies. Sex pen syringe. The syringe is a familiar product that is highly competitive and well suited for high-volume production, allowing for faster, more efficient and cost-effective time-to-market. The product will be exhibited at Pharmapack Europe (Booth B72).

"The pen injector is an important addition to Philips-Medisize's expanding portfolio of products and platforms, allowing biopharmaceutical companies to accelerate growth at scale," said Paul Chaffin, senior vice president and president of the Medical and Pharmaceutical Solutions Group at Molex. Launch new and generic treatments with clear economies of scale," added Paul. "This ready-to-use solution offers all the benefits of a state-of-the-art pen design while benefiting from our expertise in device development and high-volume manufacturing. With decades of expertise, we enable the pharmaceutical community to meet the challenges of bringing drugs and their delivery equipment to the market at affordable prices.”

Flexible design, smaller form factor, lower cost

This pen injector is designed to meet the familiar user expectations and experience of disposable pen products, but is significantly smaller than most similar products on the market. In addition to its compact form factor, this pen injector features a flexible design with customizable dosing and button colors to indicate different dosing and medication needs for a variety of treatments including diabetes, fertility, growth hormone, obesity and Osteoporosis treatment. 

Molex provides device samples for technology evaluation and human factors studies. The clinical device is planned to be launched by the end of 2023. The pen injector offers powerful advantages that can help pharmaceutical companies meet the needs of the rapidly growing disposable pen injector market, which exceeds 1 billion units, while reducing commercialization costs and risks.

Expand product portfolio 

As a global leader in end-to-end integrated solutions, Phillips-Medisize produces nearly 400 million medical devices for customers each year. For decades, Phillips-Medisize has built trusted relationships with pharmaceutical companies, delivering off-the-shelf device platforms and designing, developing and manufacturing complex or specialized devices and advanced drug delivery solutions with embedded connectivity.

The pen injector platform joins Phillips-Medisize’s Aria smart auto-injector, which was launched in May 2021 and is designed to meet the growing demand for innovative, differentiated and environmentally friendly products in the digital drug delivery device market. By introducing pen injectors, Phillips-Medisize can provide biopharmaceutical companies with more choices in the two largest injector market segments, combined with leading contract manufacturing and development capabilities to deliver highly competitive products.

Global reach and resources

Phillips-Medisize continues to invest in expanding production capacity, capability building and factory layout to streamline the development and delivery of disruptive products and solutions. Currently, the company has 32 world-class factories in 11 countries around the world and is committed to providing one-stop medical device manufacturing solutions.

Phillips-Medisize values ​​design for manufacturability and assembly excellence, as well as complex molding techniques, drug and reagent handling, and final product packaging and serialization. Together, these end-to-end capabilities enable customers to consolidate their global supply chains while optimizing go-to-market strategies.

Phillips-Medisize brings possibilities to life

Phillips-Medisize, a Molex company, brings decades of innovation experience to leading healthcare and life sciences companies to develop breakthrough solutions that help people live healthier, more productive lives. The company commercializes an average of 50 new products each year, becoming the product design, development and manufacturing partner of choice for customers around the world.